BioSepra Announces Major Management Appointment; Former General Manager from Boston Scientific becomes President of BioSepra's Medical Business.

MARLBOROUGH, Mass.--(BW HealthWire)--Feb. 3, 1999--BioSepra Inc. (OTC Bulletin Board:BSEP) today announced that John M. Carnuccio, former vice president and general manager of Boston Scientific's Microvasive Urology Division, joined BioSepra to lead its Medical Business.

Under the management of John Carnuccio, BioSepra will seek to develop and implement the Company's patented emulsion technology and biocompatible beads, called Embospheres(tm), used for blood vessel occlusion to starve hypervascularized tumors. On January 5, 1999, the Company announced the acquisition of BioSphere Medical, S.A., which has already sold the Embospheres product in Europe for the treatment of hypervascularized tumors and arteriovenous malformation. To date, more than 1,000 patients in Europe have been treated.

"I believe that I have with BioSepra an unequalled opportunity to take an early stage technology, which has been successfully sold in Europe for neurovascular applications, and expand its use into a large under met medical need -- the treatment of uterine fibroids, with a prevalence of 5,000,000 symptomatic cases in the United States alone," stated John M. Carnuccio. "Current treatment modalities range from conservative medical management -- often postponing surgical intervention -- to hysterectomy, which is frequently accompanied by complications. This provides an excellent opportunity for the development of less invasive and highly effective therapy."

"We are very fortunate to attract an individual of John Carnuccio's caliber, says Jean-Marie Vogel, president and CEO of BioSepra. He brings to BioSepra over 20 years of broad management experience in less-invasive medical device therapies for the cardiovascular, vascular and non-vascular markets. Most recently, he grew Boston Scientific's Microvasive Urology Division from less than $10 million to over $100 million in sales. This is precisely the type of leadership we need to take advantage of this unique patented technology and market opportunity."

BioSepra supplies its process chromatography media and other proprietary products to drug manufacturers for use in the commercial production of a wide range of biopharmaceuticals, including interferons, insulin, human growth hormone, special enzymes and vaccines. Over the past several years, BioSepra has collaboratively worked with the Neuroradiology Department of Hospital Lariboisiere in Paris to develop the patented Embospheres product. At the end of 1997, the Company obtained exclusive rights to this technology. BioSepra also owns significant product technology for potential use in tissue reconstruction, bulking and treatment of hypervascularized tumors.

This press release contains forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual events to differ materially from those indicated by forward-looking statements in this release are the failure of the Company to achieve or maintain necessary regulatory approvals, either in the United States or internationally, with respect to the manufacture and sale of its products; the absence of, or delays and cancellations of, product orders; delays in the development and approval of biopharmaceuticals, particularly monoclonal-based drugs; the delay in the introduction of new products; competitive pressures; the inability of the Company to raise additional funds, if needed, to finance the development, marketing and sale of its products; general economic conditions; as well as those risk factors detailed in the periodic reports filed by the Company with the Securities and Exchange Commission.